Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Changes of Pulmonary Pathology and Gene Expressions After Simvastatin Treatment in the Monocrotaline-Induced Pulmonary Hypertension Rat Model

  • Lee, Yun-Hee (Department of Pediatrics, School of Medicine, Ewha Womans University) ;
  • Kim, Kwan-Chang (Department of Thoracic and Cardiovascular Surgery, School of Medicine, Ewha Womans University) ;
  • Cho, Min-Sun (Department of Pathology, School of Medicine, Ewha Womans University) ;
  • Hong, Young-Mi (Department of Pediatrics, School of Medicine, Ewha Womans University)
  • Published : 2011.09.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: Simvastatin's properties are suggestive of a potential pathophysiologic role in pulmonary hypertension. The objectives of this study were to investigate changes of pulmonary pathology and gene expressions, including endothelin (ET)-1, endothelin receptor A (ERA), inducible nitric oxide synthase (NOS2), endothelial nitric oxide synthase (NOS3), matrix metalloproteinase (MMP) 2, tissue inhibitor of matrix metalloproteinases (TIMP) and caspase 3, and to evaluate the effect of simvastatin on monocrotaline (M)-induced pulmonary hypertension. Materials and Methods: Six week old male Sprague-Dawley rats were treated, as follows: control group, subcutaneous (sc) injection of saline; M group, sc injection of M (60 mg/kg); and simvastatin group, sc injection of M (60 mg/kg) plus 10 mg/kg/day simvastatin orally. Results: On day 28, right ventricular hypertrophy (RVH) significantly decreased in the simvastatin group compared to the M group. Similarly, right ventricular pressure significantly decreased in the simvastatin group on day 28. From day 7, the ratio of medial thickening of the pulmonary artery was significantly increased in the M group, but there was no significant change in the simvastatin group. The number of muscular pulmonary arterioles was significantly reduced in the simvastatin group. On day 5, gene expressions of ET-1, ERA, NOS2, NOS3, MMP and TIMP significantly decreased in the simvastatin group. Conclusion: Administration of simvastatin exerted weak inhibitory effects on RVH and on the number of muscular pulmonary arterioles, during the development of M-induced pulmonary hypertension in rats. Simvastatin decreased gene expressions on day 5.

Keywords

References

  1. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(Suppl S):13S-24S. https://doi.org/10.1016/j.jacc.2004.02.029
  2. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004;109:159-65. https://doi.org/10.1161/01.CIR.0000102381.57477.50
  3. Meininger GA, Davis MJ. Cellular mechanisms involved in the vascular myogenic response. Am J Physiol 1992;263:H647-59.
  4. Keck EW. Pulmonary hypertension and pulmonary vascular disease in congenital heart defects. Z Kardiol 1989;78(Suppl 7):65-73.
  5. Yamaki S, Endo M, Takahashi T. Different grades of medial hypertrophy and intimal changes in small pulmonary arteries among various types of congenital heart disease with pulmonary hypertension. Tohoku J Exp Med 1997;182:83-91. https://doi.org/10.1620/tjem.182.83
  6. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988;333:664-6. https://doi.org/10.1038/333664a0
  7. Todd L, Mullen M, Olley PM, Rabinovitch M. Pulmonary toxicity of monocrotaline differs at critical periods of lung development. Pediatr Res 1985;19:731-7. https://doi.org/10.1203/00006450-198507000-00019
  8. Girgis RE, Li D, Zhan X, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003;285:H938-45. https://doi.org/10.1152/ajpheart.01097.2002
  9. Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002;166:1403-8. https://doi.org/10.1164/rccm.200203-268OC
  10. Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003;108:1640-5. https://doi.org/10.1161/01.CIR.0000087592.47401.37
  11. McMurtry MS, Bonnet S, Michelakis ED, Bonnet S, Haromy A, Archer SL. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamycin-atorva-statin-simvastatin study. Am J Physiol Lung Cell Mol Physiol 2007; 293:L933-40. https://doi.org/10.1152/ajplung.00310.2006
  12. Kim MY, Kim YK, Jung YW, Kim WT, Kwon TH, Lee DS. The protective effect of simvastatin on monocrotaline-induced pulmonary hypertension in rats. Korean Circ J 2008;38:313-9. https://doi.org/10.4070/kcj.2008.38.6.313
  13. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006;291:L668-76. https://doi.org/10.1152/ajplung.00491.2005
  14. Lim KA, Shim JY, Cho SH, Kim KW, Han JJ, Hong YM. Effect of endothelin receptor blokade on monocrotaline-induced pulmonary hypertension in rats. Korean J Pediatr 2009;52:689-95. https://doi.org/10.3345/kjp.2009.52.6.689
  15. Lim KA, Kim KC, Cho MS, Lee BE, Kim HS, Hong YM. Gene expression of endothelin-1 and endothelin receptor A on monocrotaline-induced pulmonary hypertension in rats after bosentan treatment. Korean Circ J 2010;40:459-64. https://doi.org/10.4070/kcj.2010.40.9.459
  16. Koo HS, Kim KC, Hong YM. Gene expression of nitric oxide synthase and matrix metalloproteinase-2 in monocrotaline-induced pulmonary hypertension in rats after bosentan treatment. Korean Circ J 2010;41:83-90.
  17. Miyauchi T, Yorikane R, Sakai S, et al. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotalin-induced pulmonary hypertension. Circ Res 1993;73:887-97. https://doi.org/10.1161/01.RES.73.5.887
  18. Itoh T, Nagaya N, Fujii T, et al. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:34-8. https://doi.org/10.1164/rccm.200303-346OC
  19. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13. https://doi.org/10.1161/01.CIR.101.2.207
  20. Beckman JS, Koppenol WH. Nitric oxide, superoxide and peroxynitrite: the good, the bad, and the ugly. Am J Physiol 1996;271:C1424-37.
  21. Hampl V, Herget J. Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. Physiol Rev 2000;80:1337-72. https://doi.org/10.1152/physrev.2000.80.4.1337
  22. Miller AA, Hislop AA, Vallance PJ, Haworth SG. Deletion of the eNOS gene has a greater impact on the pulmonary circulation of male than female mice. Am J Physiol Lung Cell Mol Physiol 2005;289:L299-306. https://doi.org/10.1152/ajplung.00022.2005
  23. Li M, Li Z, Sun X. Statins suppress MMP2 secretion via inactivation of RhoA/ROCK pathway in pulmonary vascular smooth muscle cells. Eur J Pharmacol 2008;591:219-23. https://doi.org/10.1016/j.ejphar.2008.06.082
  24. Girgis RE, Mozammel S, Champion HC, et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 2007;292:L1105-10. https://doi.org/10.1152/ajplung.00411.2006
  25. Kim YC, Song SB, Lee MH, et al. Simvastatin induces caspase-independent apoptosis in LPS-activated RAW264.7 macrophage cells. Biochem Biophys Res Commun 2006;339:1007-14. https://doi.org/10.1016/j.bbrc.2005.11.099
  26. Kaneta S, Satoh K, Kano S, Kanda M, Ichihara K. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis 2003;170:237-43. https://doi.org/10.1016/S0021-9150(03)00301-0
  27. Kubota T, Fujisaki K, Itoh Y, Yano T, Sendo T, Oishi R. Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors. Biochem Pharmacol 2004;67:2175-86. https://doi.org/10.1016/j.bcp.2004.02.037
  28. Wilkins MR, Ali O, Bradlow W, et al. Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med 2010;181:1106-13. https://doi.org/10.1164/rccm.2009111-699OC
  29. Liu B, Wang XQ, Yu L, Zhou TF, Wang XM, Liu HM. Simvastatin restores down-regulated GATA-6 expression in pulmonary hypertensive rats. Exp Lung Res 2009;35:411-26. https://doi.org/10.1080/01902140902736819

Cited by

  1. Differential effect of mild and severe pulmonary embolism on the rat lung transcriptome vol.17, pp.None, 2011, https://doi.org/10.1186/s12931-016-0405-9
  2. Simvastatin prevents and reverses chronic pulmonary hypertension in newborn rats via pleiotropic inhibition of RhoA signaling vol.311, pp.5, 2011, https://doi.org/10.1152/ajplung.00345.2016
  3. Microarray Analysis in Pulmonary Hypertensive Rat Heart after Simvastatin Treatment vol.41, pp.3, 2018, https://doi.org/10.12771/emj.2018.41.3.53